Evan Waxman

Prof. Evan Waxman

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in Ophthalmology
Verified
Journal Article
Closed access
MSManjool Shah
Manjool Shah
DKDaniel Knoch
Daniel Knoch
EWEvan Waxman
Evan Waxman

28 April 1992 in Biochemistry
Verified
Journal Article
Closed access
EWEvan Waxman
Evan Waxman
JRJ. B. Alexander Ross
J. B. Alexander Ross
TLThomas M. Laue
Thomas M. Laue
AGArabinda Guha
Arabinda Guha
STS. V. Thiruvikraman
S. V. Thiruvikraman
YNYale Nemerson
Yale Nemerson

6 May 2020 in Ophthalmology and Therapy
Verified
Journal Article
Open access
PDF file
AWAndrew M. Williams
Andrew M. Williams
Gagan KalraGagan Kalra
Gagan Kalra
PCPatrick W. Commiskey
Patrick W. Commiskey
EBEve M. R. Bowers
Eve M. R. Bowers
BRBrian R. Rudolph
Brian R. Rudolph
RFRoxana Fu
Roxana Fu
The coronavirus disease 2019 pandemic has led to widespread change as public health strategies for containment have emphasized social distancing and remaining at home. These policies have led to downscaled clinic volumes, cancellation of elective procedures, enhanced personal protective strategies in the clinic, and adoption of telemedicine encounters. We describe the evidence-based practical approach taken in our ophthalmology department to continue delivering eye care during the pandemic by rescheduling visits, enhancing clinic safety, and adopting virtual video encounters.

1 March 1993 in Biochemistry
Verified
Journal Article
Closed access
EWEvan Waxman
Evan Waxman
WLWilliam R. Laws
William R. Laws
TLThomas M. Laue
Thomas M. Laue
YNYale Nemerson
Yale Nemerson
JRJ. B. Alexander Ross
J. B. Alexander Ross

22 June 1993 in Biochemistry
Verified
Journal Article
Closed access
DSDonald F. Senear
Donald F. Senear
TLThomas M. Laue
Thomas M. Laue
JRJ. B. Alexander Ross
J. B. Alexander Ross
EWEvan Waxman
Evan Waxman
SESteven Eaton
Steven Eaton
ERElena Rusinova
Elena Rusinova

16 February 2016 in BMJ Open Diabetes Research & Care
Verified
Journal Article
Open access
PDF file
JKJessica J Kovarik
Jessica J Kovarik
AEAndrew W Eller
Andrew W Eller
LWLauren A Willard
Lauren A Willard
JDJiaxi Ding
Jiaxi Ding
JJJann M Johnston
Jann M Johnston
EWEvan Waxman
Evan Waxman
Objective To determine the prevalence and risk factors of diabetic retinopathy in the inpatient diabetic population in the USA and to determine the barriers to ophthalmic examinations and treatment among this population. Research design and methods A cross-sectional analysis of 113 inpatients with diabetes mellitus admitted to an inner city community teaching hospital in Pittsburgh. Digital fundus photographs of the posterior pole were taken of each eye after pharmacological dilation. Presence, absence and severity of diabetic retinopathy and macular edema were graded on the basis of internationally accepted criteria. An investigator-administered questionnaire and review of the medical record were used to obtain data about patient demographics, clinical characteristics and barriers to ophthalmic care. The association between these data and the presence of diabetic retinopathy was tested. Results The estimated prevalence of diabetic retinopathy in the inpatient population was 44% (95% CI 34% to 53%). The prevalence of previously undiagnosed diabetic retinopathy and sight-threatening retinopathy was 25% (95% CI 17% to 33%) and 19% (95% CI 11% to 26%), respectively. Renal disease was independently associated with the presence of diabetic retinopathy (OR, 3.86; 95% CI 1.22 to 12.27), as well as a longer duration of diabetes (OR, 1.08 per year; 95% CI 1.014 to 1.147). Diabetic retinopathy was seen in 15 of 17 patients admitted with diabetic foot ulcers or osteomyelitis. Frequently reported barriers to ophthalmic examinations included lack of transportation and physical disability. Conclusions The prevalence of diabetic retinopathy and sight-threatening diabetic retinopathy in the inpatient population is likely significantly higher than in the general diabetic population in the USA. These patients have barriers to care that need to be addressed to make standard of care ophthalmic examinations and treatment possible in this population.